- Molecular NameDaptomycin
- Synonymdaptomycin ; LY 146032
- Weight1620.69
- Drugbank_IDDB00080
- ACS_NO103060-53-3
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)N/A
- pkaN/A
- LogD (pH=7, predicted)N/A
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)N/A
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond DonorsN/A
- No.of HBond AcceptorsN/A
- No.of Rotatable BondsN/A
- TPSAN/A
- StatusFDA approved
- AdministrationIntravenous
- PharmacologyA novel lipopeptide antibiotic used in the treatment of certain infections caused by Gram-positive organisms.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability0.0
- Protein binding92.0
- Volume of distribution (VD)0.096 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIn vitro studies with human hepatocytes indicate that daptomycin does not inhibit or induce the activities of the following human cytochrome P450 isoforms: 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4. In in vitro studies, daptomycin was not metabolized by human liver microsomes. It is unlikely that daptomycin will inhibit or induce the metabolism of drugs metabolized by the P450 system.
- Half life7.8 h
- ExcretionRenal (78%; primarily as unchanged drug); Faeces (5.7%)
- Urinary Excretion47
- Clerance0.14 ml/min/kg
- ToxicityThe following adverse events occured with frequency more than 5%: constipation, nausea, diarrhea, injection side reactions, and headache.
- LD50 (rat)N/A
- LD50 (mouse)N/A